Press reviews
Metastatic hormone-sensitive prostate cancer (mHSPC) is an advanced stage of the disease, with a prognosis that remains concerning despite recent therapeutic advances. Standard treatment is based on androgen deprivation therapy (ADT), to which agents such as docetaxel or androgen receptor–targeted therapies (ARATs)—inc...
Testicular cancer is the most common solid tumor in young men and carries an excellent prognosis thanks to current treatments such as surgery, chemotherapy, and radiotherapy. However, fertility preservation remains a major concern, as these treatments can impair spermatogenesis, either temporarily or permanently. &n...
Metastatic castration-resistant prostate cancer (mCRPC) represents an advanced and aggressive stage of the disease in which tumor cells continue to progress despite androgen suppression. It is characterized in most cases by bone metastases, which are responsible for considerable morbidity and increased mortality. These...
Cancer treatment, whether based on chemotherapy, radiotherapy, or immunotherapy, is frequently associated with gastrointestinal side effects. These digestive symptoms have a direct impact on patients’ nutritional status and may compromise the effectiveness of oncological treatments.
Convention...
2025-11-24
Does smoking during pregnancy protect against type 1 diabetes?
Endocrinology and Metabolism
Type 1 diabetes (T1D) is a chronic autoimmune disease caused by the destruction of the β-cells of the pancreatic islets of Langerhans, leading to lifelong dependence on insulin. Its global prevalence is steadily increasing, particularly in developed countries, making T1D a major public health concern due to its m...
2025-11-24
Urology-nephrology Oncology
Radical prostatectomy (RP) remains a key treatment for men with localized prostate cancer. However, it is associated with two major side effects: urinary incontinence and erectile dysfunction, both of which significantly affect postoperative quality of life. Nerve-sparing (NS) techniques allow partial preservation of erec...
2025-11-21
Prostate cancer: could physical exercise be the key to regaining an active sexual life?
Urology-nephrology Oncology
Sexual dysfunction is a common side effect of prostate cancer treatments, impacting patients’ quality of life well beyond the acute phase of disease. Despite pharmacological progress, current therapeutic approaches often fail to sufficiently address the physical, psychological, and relational components involved. This hig...
2025-11-20
Prostatectomy or SBRT: which treatment better preserves quality of life?
Urology-nephrology Oncology
In men with localized prostate cancer at low or intermediate risk, two curative treatments are now standard options: radical prostatectomy and stereotactic body radiotherapy (SBRT). While surgery is often regarded as the more radical approach, radiotherapy is considered less invasive, but its side effects—particularly bo...
The digital rectal exam (DRE) has historically been a key tool in the early detection of prostate cancer (PCa). Before the widespread use of prostate-specific antigen (PSA) testing, DRE was the primary method for identifying potentially aggressive tumors. PSA transformed early detection by identifying cancers even in asy...
2025-11-19
Oncology
Metastatic castration-resistant prostate cancer (mCRPC) represents an advanced stage of the disease, commonly treated with androgen deprivation therapy (ADT). Although this strategy improves survival, it often leads to a deterioration in quality of life (QoL), with side effects such as fatigue, cognitive impairment, bone...
2025-11-18
Oncology
Metastatic castration-resistant prostate cancer (mCRPC) remains an incurable disease despite a decade of significant therapeutic progress. The clinical objective is no longer limited to survival, but now also includes quality of life (QoL) and symptom control. The biological heterogeneity of mCRPC, marked by increasing g...
2025-11-17
Treatment of prostate cancer with GnRH agonists: what is the real impact on quality of life?
Urology-nephrology Oncology
Prostate cancer is one of the most common cancers in men. In advanced stages, treatment often relies on hormone therapy using GnRH (gonadotropin-releasing hormone) agonists. While this approach slows tumor progression by suppressing testosterone, it also causes significant side effects that may impair quality of life (QoL...
The emergence of immunotherapies, particularly immune checkpoint inhibitors (ICIs), has revolutionized the management of many cancers. However, only a minority of patients derive durable benefit. Current biomarkers such as PD-L1 expression, tumor mutational burden (TMB), and microsatellite instability (MSI) have significa...
2025-11-13
Oncology
Metastatic castration-sensitive prostate cancer (mCSPC) remains a major public health challenge for men worldwide. Historically, its management relied on androgen deprivation therapy (ADT) alone. However, advances in understanding the androgen receptor (AR) signaling pathway have profoundly changed therapeutic strategies...
2025-11-12
Darolutamide: Will it redefine the initial treatment strategy in metastatic prostate cancer?
Oncology
For many years, metastatic castration-sensitive prostate cancer (mCSPC) was treated exclusively with androgen deprivation therapy (ADT). However, recent therapeutic advances have led to the emergence of combination strategies, particularly those involving androgen receptor signaling inhibitors (ARSi). Among these agents,...
